Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent.
| Image |  |
|---|---|
| Description | scientific article published on 10 March 2009 |
| Author/s |
author: John M Ebos |
| Publication date | March 10, 2009 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |